Probiotic Strains for IBS: Which Species the Evidence Actually Supports

Probiotic capsules marketed for irritable bowel syndrome (IBS) routinely list 10 or 20 different strains and dose counts in the billions. The major gastroenterology societies — the American College of Gastroenterology, the British Society of Gastroenterology, and the World Gastroenterology Organisation — agree on a different message: clinical effects in IBS are strain-specific, the field is heterogeneous, and most marketed multi-strain blends do not have human trials. Knowing which strains have evidence and which subtype of IBS they target is the only honest way to choose.

Why "strain" matters more than "species"

Bacteria classified within the same species can behave very differently. Two strains of Lactobacillus plantarum can produce different metabolites, adhere differently to intestinal cells, and have different antibiotic resistance patterns. Probiotic trials report specific strain identifiers (for example, "299v" for L. plantarum) and effects do not extrapolate across strains within the same species. When a product simply says "Lactobacillus acidophilus" without a strain identifier, there is no way to know what was actually tested [1].

Strains with positive RCTs in IBS

The 2023 ACG IBS guideline and the 2022 BSG meta-analysis identified a small set of strains with reproducible RCT evidence [2]. Bifidobacterium infantis 35624 (now reclassified as B. longum subspecies infantis) reduced global IBS symptom scores in two multi-centre trials. Lactobacillus plantarum 299v improved bloating and abdominal pain in IBS-D in three smaller trials. Saccharomyces boulardii CNCM I-745 reduced IBS-D stool frequency in two trials and is a yeast rather than a bacterium — useful in patients on antibiotics. Multi-strain combinations including De Simone formulation (formerly VSL#3) showed mixed but generally positive effects on IBS quality of life [3].

IBS subtype matters

The most useful frame is matching strain to IBS subtype:

IBS-D (diarrhoea predominant): S. boulardii CNCM I-745 is the most consistent. L. plantarum 299v has some data here. Soil-based Bacillus strains have been promoted but the trial data are thin.

IBS-C (constipation predominant): B. lactis HN019 produced significant reductions in whole-gut transit time in a 2011 trial. Combination with L. acidophilus NCFM has some additive data.

IBS-M (mixed) and IBS-U (global symptoms): B. infantis 35624 has the broadest signal across symptom domains. The De Simone formulation has trials in mixed populations.

Dose, duration, and viability

Trial doses cluster between 10⁸ and 10¹⁰ colony-forming units (CFU) per day. Duration matters: most trials show that a 4-week trial is enough to detect a real response. If 8 weeks of consistent use at trial dose produces no benefit, the specific strain is unlikely to work for that person. Many marketed products use lower CFU than trials tested; the label should specify CFU "at end of shelf life," not "at time of manufacture" — the latter can be 10× higher [4].

What does not work

Single-strain Lactobacillus rhamnosus GG, despite being the most-studied probiotic overall, has consistently failed to improve IBS symptoms in placebo-controlled trials [5]. Most generic "yogurt cultures" or kefir mixes do not contain the IBS-tested strains. Soil-based organisms (SBOs) like Bacillus subtilis are heavily marketed but their IBS trials are small, often industry-funded, and inconsistent.

Safety considerations

Probiotics are generally safe in immunocompetent adults. The main contraindications are central venous catheters, severe immunocompromise, and acute pancreatitis (where a high-profile RCT showed harm from a multi-strain product). Anyone with these conditions should not take probiotics without medical supervision [6]. Yeast-based probiotics like S. boulardii are contraindicated in critically ill patients with indwelling catheters because of rare fungaemia.

Practical takeaway

If IBS is the indication, choose a product with one or two evidence-based strains at trial-dose CFU rather than a "kitchen sink" multi-strain blend. Try the matched strain for 4–8 weeks. If no response, switch strain rather than escalate dose. Probiotics are an adjunct to first-line interventions — low-FODMAP diet trial, soluble fibre, antispasmodics, and gut-directed cognitive behavioural therapy — and should not be expected to substitute for them.